GEORGE J BREWER, M.D.
Medical Practice at Zina Pitcher Pl, Ann Arbor, MI
License number
Michigan 43-01028446
Category
Medical Practice
Type
Specialist
Address
Address
205 Zina Pitcher Pl, Ann Arbor, MI 48109
Phone
(734) 764-5499
(734) 615-2048 (Fax)
(734) 615-2048 (Fax)
Personal information
See more information about GEORGE J BREWER at radaris.comName
Address
Phone
57 N Bock Rd, Muskegon, MI 49442
4384 Old Baker Rd, Bridgeport, MI 48722
416 Charles St, Paw Paw, MI 49079
9340 Ryan Rd, Atlanta, MI 49709
8630 N Gregory Rd, Fowlerville, MI 48836
Organization information
See more information about GEORGE J BREWER at bizstanding.comGEORGE J. BREWER, INC
Ann Arbor, MI
Registration:
Apr 17, 2006
Addresses:
3820 Gensley Rd, Ann Arbor, MI 48103 (Physical)
Michigan (Mailing)
Michigan (Mailing)
State ID:
09762E
Business type:
Domestic Profit Corporation
Agent:
George J Brewer
Professional information
George J Brewer, Ann Arbor MI
Specialties:
Internal Medicine, Medical Genetics
Work:
University of Michigan Hospitals & Health Centers
1500 E Medical Center Dr, Ann Arbor, MI 48109
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
University of Chicago (1956)
Dr. George J Brewer, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
205 Zina Pitcher Pl, Ann Arbor 48109
(734) 764-5499 (Phone), (734) 615-2048 (Fax)
(734) 764-5499 (Phone), (734) 615-2048 (Fax)
Languages:
English
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1956
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1956
Dna Encoding Canine Von Willebrand Factor And Methods Of Use
US Patent:
6780583, Aug 24, 2004
Filed:
Sep 15, 2000
Appl. No.:
09/662478
Inventors:
Patrick J. Venta - Pinckney MI
George J. Brewer - Ann Arbor MI
Vilma Yuzbasiyan-Gurkan - Ann Arbor MI
William D. Schall - Williamston MI
George J. Brewer - Ann Arbor MI
Vilma Yuzbasiyan-Gurkan - Ann Arbor MI
William D. Schall - Williamston MI
Assignee:
Board of Trustees Operating Michigan State University - Ann Arbor MI
International Classification:
C12Q 168
US Classification:
435 6, 435 912, 4352523, 435325, 536 221, 536 243
Abstract:
The complete sequence of the canine von Willebrand Factor cDNA and deduced amino acid sequence is provided. The mutation which causes von Willebrands Disease in Scottish Terriers, Doberman pinschers, Shetland sheepdogs, Manchester terriers and Poodles are also provided. Methods for detecting carriers of the defective vWF gene are also provided.
Copper Lowering Treatment Of Inflammatory And Fibrotic Diseases
US Patent:
2007024, Oct 25, 2007
Filed:
Mar 6, 2007
Appl. No.:
11/714588
Inventors:
George Brewer - Ann Arbor MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 33/24, A61P 11/00
US Classification:
424617000
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate wherein exemplary thiotungstates include mono-, di-, tri-. And tetrathiotungstate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Copper Lowering Treatment Of Inflammatory And Fibrotic Diseases
US Patent:
6855340, Feb 15, 2005
Filed:
May 23, 2003
Appl. No.:
10/444204
Inventors:
George J. Brewer - Ann Arbor MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
A01N059/20, A61K033/34, A61K031/30
US Classification:
424630, 424637, 424646, 514499
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Copper Lowering Treatment Of Inflammatory And Fibrotic Diseases
US Patent:
2007029, Dec 27, 2007
Filed:
May 29, 2007
Appl. No.:
11/807441
Inventors:
George Brewer - Ann Arbor MI, US
International Classification:
A61K 33/26, A61K 39/395, A61P 13/12
US Classification:
424130100, 424646000
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Copper Lowering Treatment Of Inflammatory And Fibrotic Diseases
US Patent:
7416741, Aug 26, 2008
Filed:
Feb 14, 2005
Appl. No.:
11/057353
Inventors:
George J. Brewer - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A01N 59/20, A61K 33/34, A61K 31/30
US Classification:
424630, 424637, 424646, 514499
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Copper Lowering Treatment Of Inflammatory And Fibrotic Diseases
US Patent:
2007029, Dec 27, 2007
Filed:
May 29, 2007
Appl. No.:
11/807434
Inventors:
George Brewer - Ann Arbor MI, US
International Classification:
A61K 33/26, A61K 31/131, A61K 31/197, A61K 31/4704
US Classification:
424646000, 514311000, 514562000, 514674000
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Dna Encoding Canine Von Willebrand Factor And Methods Of Use
US Patent:
6074832, Jun 13, 2000
Filed:
Aug 11, 1998
Appl. No.:
9/132652
Inventors:
Patrick J. Venta - Pinckney MI
George J. Brewer - Ann Arbor MI
Vilma Yuzbasiyan-Gurkan - Ann Arbor MI
William D. Schall - Williamston MI
George J. Brewer - Ann Arbor MI
Vilma Yuzbasiyan-Gurkan - Ann Arbor MI
William D. Schall - Williamston MI
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 170, C12P 1934, C07H 2104, C12N 120
US Classification:
435 6
Abstract:
The complete sequence of the canine von Willebrand Factor cDNA and deduced amino acid sequence is provided. The mutation which causes von Willebrand's Disease in Scottish Terriers, Doberman pinschers, Shetland sheepdogs, Manchester terriers and Poodles are also provided. Methods for detecting carriers of the defective vWF gene are also provided.
Copper Lowering Treatment Of Autoimmune Diseases
US Patent:
2007029, Dec 20, 2007
Filed:
Apr 26, 2007
Appl. No.:
11/789999
Inventors:
George Brewer - Ann Arbor MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 33/24, A61P 19/02, A61P 37/00
US Classification:
424646000
Abstract:
The present invention relates generally to the field of prophylaxis and therapy for autoimmune diseases. In particular, the present invention is related to agents that can bind or complex copper, and to the use of these agents in the prevention and/or treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis, and multiple sclerosis.
Medical Practice licenses in Michigan
GERALD A SERWER, Medical Practice, 1500 C.S. Mott Childrens Hospital FLOOR 11TH, Ann Arbor, MI 48109